Raphael Pharmaceutical (RAPH) Liabilities and Shareholders Equity (2020 - 2025)

Raphael Pharmaceutical has disclosed Liabilities and Shareholders Equity across 6 years of filings, most recently posting $53000.0 for Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $53000.0, up 96.3% year-over-year; the trailing twelve-month figure through Dec 2025 was $183000.0 (down 67.26% YoY), and the FY2025 annual result was $53000.0, up 96.3% from the prior year.
• Liabilities and Shareholders Equity came in at $53000.0 for Q4 2025 at Raphael Pharmaceutical, up from $7000.0 in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $422000.0 in Q4 2021 to a low of $7000.0 in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $124500.0 (2022), against an average of $164833.3.
• Across the five-year window, Liabilities and Shareholders Equity surged 233.06% in 2023 and plunged 88.7% in 2024, its largest moves.
• Raphael Pharmaceutical's Liabilities and Shareholders Equity stood at $422000.0 in 2021, then retreated by 21.09% to $333000.0 in 2022, then declined by 28.23% to $239000.0 in 2023, then slumped by 88.7% to $27000.0 in 2024, then surged by 96.3% to $53000.0 in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $53000.0 (Q4 2025), $7000.0 (Q3 2025), and $30000.0 (Q2 2025), per Business Quant data.